ALK and non-small cell lung carcinoma: Given the absence of discernible benefits in the mutant subgroups of the KEYNOTE-091 and IMpower010 studies, coupled with the positive outcomes exhibited in two large global phase III trials, ADAURA (63) and ALINA (64), the recommended strategy for patients with resected driver gene-positive (EGFR/ALK-positive) resectable NSCLC is to proceed with surgical intervention followed by adjuvant targeted therapy exclusively.